Boston Immune Technologies and Therapeutics (BITT)
Company Details
Status: Private
Employees: 1-10
Location:
Boston, Massachusetts, United States
Type:
sample
Technology:
sample
sample
About: BITT’s dominant antibody antagonist antibody platform (DOMabTM) is a proprietary discovery platform for the development of antagonist monoclonal antibodies to the TNF superfamily. DOMab antibodies create unique surface stabilization of anti-parallel dimers for altering intracellular signaling. For TNF superfamily proliferative pathways (such as TNFR2, TRAIL and HVEM), antagonism causes cell death. For death receptors (such as CD40, CD27 and OX40), antagonism permits cell growth. Our technology’s ability to create antibodies that target only rapidly proliferating cells opens the door to TNF superfamily targets that were previously considered undruggable or limited by toxicology.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Boston Immune Technologies and Therapeutics (BITT) | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.